HBE1 and fibrosis: Successful immune activity in the immune-clearance phase results in HbeAg loss, the development of anti-Hbe antibodies and thus a transition to the inactive carrier state; whereas other patients who have no serologic clearance may have liver damage, which may lead to fibrosis, cirrhosis and a higher risk of HCC [67].